{
  "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a",
  "docSlug": "ddfbb08119f4",
  "documentTitle": "Multiple holdings (Pershing Square portfolio)",
  "authorId": "01_Pershing_Square",
  "authorName": "Pershing Square",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2016-04-26 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 50,
  "pageCount": 82,
  "prevPage": 49,
  "nextPage": 51,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "callout_box",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/50",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-50",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.0016799999999999999
      },
      "kind": "callout",
      "text": "Papa’s scientific and industry background, shareholder orientation, history of commercial excellence, and strong ethics make him the ideal leader for Valeant",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d227ac-92b5-4065-8ceb-1b732479b205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.0029500000000000004
      },
      "kind": "list",
      "text": "Papa has spent his career in the pharmaceutical industry, most recently as CEO of Perrigo, which specializes in OTC and generic drugs. Papa has more than 35 years of experience in the pharmaceutical, healthcare services and specialty pharmaceutical industries, including 20 years of branded prescription drug experience.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56e7c00f-e222-42a9-8527-84e1a6f569b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.00515
      },
      "kind": "list",
      "text": "At Perrigo, Papa built a strong operational performance track record. Consistent strategy to deliver quality, affordable healthcare products. Averaged 6% “same store” organic revenue growth since 2008. 1,100 bps increase in operating margin of company’s largest segment since 2007. 29% annualized EPS growth since 2007, driven by organic growth and capital allocation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85ac4140-9808-44ae-ae7c-0b60808b06ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.00805
      },
      "kind": "list",
      "text": "Impressive shareholder return track record. Perrigo shareholders enjoyed a 24% annualized return during Papa’s tenure. The S&P Healthcare index realized a 10% annualized return during same period.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6e316ce-4145-4104-8a40-b897af0d2f89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "annualized return: 24%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b39c-bb7a18127104",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.0095
      },
      "kind": "source-note",
      "text": "1Perrigo company presentation (“Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender ”), September 2015, Page 23. 2By revenue",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "009c798e-39b4-4403-8b9b-8185aca59076",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.18,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Joe Papa",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a006938b-2dc7-424a-9add-227b3762e7cf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 55,
      "from": 46,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f7114afd-038c-43c2-aca5-af6c97fbebf1",
      "evidence": "The presentation highlights the decline of Valeant and Platform Specialty Products Corporation.",
      "position": 1,
      "objective": "What are the consequences of not taking action?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}